Article Text

other Versions

Download PDFPDF
Systematic review and meta-analysis
Network meta-analysis demonstrates the safety of pharmacotherapy for smoking cessation in cardiovascular patients
  1. Andrew L Pipe
  1. Heart Institute, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
  1. Correspondence to: Professor Andrew L Pipe, University of Ottawa Heart Institute, 40 Ruskin St, Ottawa, Ontario, Canada K1Y 4W7; apipe{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


The importance of smoking cessation in the prevention and management of cardiovascular disease cannot be overestimated. Exposure to tobacco products, beginning in utero, causes substantial damage to vascular health, imposing dramatic public and personal health burdens over a lifetime. Smokers lose, on average, 10 years of life expectancy.1 Smoking cessation is the most powerful preventive intervention available—particularly to those already suffering from cardiovascular disease.2 Systematic approaches to the identification and treatment of smokers with front-line pharmacotherapies, particularly in cardiovascular settings, have demonstrated significant benefit in inducing and maintaining …

View Full Text


  • Competing interests ALP has served as an advisory board member and has received research support from Pfizer; and served as an advisory board member for Johnson & Johnson, GSK and Amgen.